Scarica l'app Stockscreener
2.37
17.71%
-0.51
Pre-mercato:
2.67
0.30
+12.66%
Precedente Chiudi:
$2.88
Aprire:
$2.53
Volume 24 ore:
363.84K
Relative Volume:
0.72
Capitalizzazione di mercato:
$3.55M
Reddito:
-
Utile/perdita netta:
$-17.06M
Rapporto P/E:
-0.0335
EPS:
-70.7173
Flusso di cassa netto:
$-14.18M
1 W Prestazione:
-66.74%
1M Prestazione:
-55.20%
6M Prestazione:
-75.69%
1 anno Prestazione:
-99.65%
Intervallo 1D:
$2.238
$2.68
Intervallo di 1 settimana:
$2.238
$5.15
Portata 52W:
$2.238
$1,195.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Nome
Cns Pharmaceuticals Inc
Settore
Industria
Telefono
1-800-946-9185
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Confronta CNSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
2.37 | 3.55M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Iniziato | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference - The Globe and Mail
CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN
CNSPCNS Pharmaceuticals Latest Stock News & Market Updates - StockTitan
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum - ACCESS Newswire
Can CNS Pharmaceuticals' Brain Cancer Breakthrough Change Treatment Landscape? CEO Presents Next Week - StockTitan
CNS Pharmaceuticals enacts 1-for-50 reverse stock split - Investing.com
CNSP stock touches 52-week low at $0.08 amid sharp annual decline - Investing.com India
CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down -February 19, 2025 at 10:28 am EST - Marketscreener.com
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - StockTitan
Can This Drastic 1:50 Reverse Split Save CNS Pharmaceuticals' Nasdaq Listing? - StockTitan
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit - The Globe and Mail
CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit - TipRanks
Revolutionary Brain Barrier-Crossing Cancer Drug Takes Center Stage at GBM Summit - StockTitan
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) - ACCESS Newswire
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
CNSP’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Does Cns Pharmaceuticals Inc (CNSP) offer a good opportunity for investors? - SETE News
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference - ACCESS Newswire
CNS Pharma's Breakthrough Brain Cancer Pipeline Takes Center Stage at Elite BIO CEO Conference - StockTitan
Key Market Driver in Generic Central Nervous System Drugs Industry 2025: Rising Incidence Of Mental Health ... - WhaTech
Ladenburg Thalmann slashes price target on Cns Pharmaceuticals Inc [CNSP] – find out why. - The DBT News
Cns Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
CNSP’s price-to-book ratio: An indicator of the company’s performance - US Post News
Boston biotech Atalanta raises $97M to bring CNS drugs into clinic - The Business Journals
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - ACCESS Newswire
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference - ACCESS Newswire
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment - ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity - ACCESS Newswire
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference - ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - ACCESS Newswire
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - ACCESS Newswire
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date - ACCESS Newswire
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) - ACCESS Newswire
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering - ACCESS Newswire
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - ACCESS Newswire
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results - ACCESS Newswire
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - ACCESS Newswire
CNS Pharmaceuticals Announces Reverse Stock Split - ACCESS Newswire
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea - Business Wire
Central Nervous System (CNS) Therapeutics Market Forecast - GlobeNewswire
Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region - 24matins.uk
CNS Pharmaceuticals (NASDAQ:CNSP) Trading Up 6.5% – Here’s Why - Defense World
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
Does Cns Pharmaceuticals Inc (NASDAQ: CNSP) Still Need To Convince Analysts? - Stocks Register
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):